Full Article
Access required
This content requires purchase or subscription access to view the full article.
Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation
By: L.L.W. Cooling, J. Sherbeck, J.C. Mowers and S.L. Hugan
Paid access
|Oct 2019DOI: https://doi.org/10.21307/immunohematology-2019-004 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 15 - 21
Published on: Oct 9, 2019
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2019 L.L.W. Cooling, J. Sherbeck, J.C. Mowers, S.L. Hugan, published by American National Red Cross
This work is licensed under the Creative Commons License.